Member Info for WeTookPelham

I lose track of all the conference types to be honest, but this one is specifically for partnering it seems. Interesting IMO.

https://www.trade.gov/germany-events-bio-europe#:~:text=BIO%2DEurope%20is%20the%20preeminent,%2C%20pharmaceutical%2C%20and%20financial%20sectors.

Agree the Scancell science is not her remit here, there are better qualified people for the job at Scancell for that. But saying that she does also seem to have a strong science background also?

https://ceoworld.biz/directory/exec/dr-mandeep-sehmi

Many strings to her bow it seems.

And what confused me was the description, sounds more scientific, no?

"...learn about Scancell Ltd exciting and innovative approaches to immunotherapy. "

But I guess not much can be inferred from the above as it's quite generic also.

Hopefully it is to arrange specific meetings with specific people. Who do we know is in Germany?

So is she there in a science capacity or a business capacity? Whilst I believe she is a multi faceted i.e.has a science background as well, I'm trying to understand her attendance purpose.

...that Dr Semhi is attending a conference on her own in Germany about now? Can't find the details.

"...How much more data does Sclp need?. Pharmas are buying out Cos with only preclinical results. IMO"

A point I've made many times Dracula1, why do Scancell, and quite a few posters seem to adhere to the "data, data, data " mantra, when as we agree, there are so many preclinical deals? A genuine question to those posters? I.e. what makes Scancell so different? I know there has always been "maximising shareholder value" thing. But a buyout/partnership now would still achieve that to a degree?

"...Surely Sclp can't attempt to go much further with present trials with the SP where It Is."

Another good point. Surely they will get to a point and say no we need to partner to really push this forward?

You'd think they specifically hired the new business development officer Dr. Semhi for the reason of wanting to sign a deal/deals sooner rather than later?

Https://jitc.bmj.com/content/11/Suppl_2/A1711

...as my previous attempt does not seem to have saved?

"A DNA plasmid melanoma cancer vaccine, SCIB1, combined with nivolumab + ipilimumab in patients with advanced unresectable melanoma: efficacy and safety results from the open-label phase 2 SCOPE trial"

Will post URL in second post in case that is the issue.

https://jitc.bmj.com/content/11/Suppl_2/A1711

Https://jitc.bmj.com/content/11/Suppl_2/A1711

Wasn't it established by someone/a few posters it was a typo?

Jmc?

Good spot jb7070. Interesting 🤔

Has it been held there before ever?

Bye then.

I'm sure with the new news about the extended cash runway there are several posters so very disappointed that they can't twist the narrative of needing a cash call etc. Diddums.

Researcher - simply sell your 'holding' and come back in 18 months. Ta ra!

Anyway your posting history shows you simply trade the stock, nothing wrong with that of course. But don't try to (badly) misinterpret the RNS for your own benefit.

... according to advfn. So the market seems to like it?

LSE seems to be having an issue with all its data ATM?

...a bunch of new/dormant posters start appearing this morning trying to twist the narrative of a results RNS by applying their 'interpretation' of the RNS.

I feel like this is a recurring pattern too.

I like DC's description of potential bulletin board de-rampers... tyre kickers:

"29/10/2023

10:09 dominiccummings: #6707 Tyre kicker - wondering if he can create a panic. Ignore him (or her) the appropriate authorities or the auditors will sort their problem."

Https://www.gov.uk/government/publications/late-filing-penalties/late-filing-penalties#late-filing-penalty-fees

@dragon101, thanks, I genuinely don't know how it works RE audit deadlines, a fine for the auditors sounds much more feasible though. I probably should be doing my own research into this though.